Plasma protein profiling of breast cancer patients of North Indian population: A potential approach to early detection

Journal of Proteomics and Bioinformatics

Volumn 6, Issue 5, 2013, Pages 88-98

  Arora, Deepika ^a   Ansari, Zafar Mahmood ^a   George, Jasmine ^a   Yadav, Alok Kumar ^a   Kumar, Shailendra ^b   Singh, Uma Shanker ^b   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Breast cancer; North India; Proteomics

Indexed keywords

AMYLOID P COMPONENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR I; FETUIN A; HAPTOGLOBIN; HISTONE DEACETYLASE; ONCOPROTEIN; PHOSPHATIDATE PHOSPHATASE; PLASMA RETINOL BINDING PROTEIN; SERPIN PEPTIDASE INHIBITOR CLADE A; TRANSFERRIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METASTASIS INHIBITION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; UPREGULATION; VALIDATION STUDY; WESTERN BLOTTING;

EID: 84878724472     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.1000267     Document Type: Article

References (64)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
2. Tria Tirona M (2013) Breast cancer screening update. Am Fam Physician 87: 274-278.
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
4. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
5. Maurya P, Meleady P, Dowling P, Clynes M (2007) Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 27: 1247-1255.
6. Sun W, Xing B, Sun Y, Du X, Lu M, et al. (2007) Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 6: 1798-1808.
7. Li Y, Zhang QL, Yang XL, Li G, He X, et al. (2012) Clusterin is a potential serum marker of hepatic carcinoma. Zhonghua Gan Zang Bing Za Zhi 20: 275-279.
8. Maltman DJ, Brand S, Belau E, Paape R, Suckau D, et al. (2011) Top-down label-free LC-MALDI analysis of the peptidome during neural progenitor cell differentiation reveals complexity in cytoskeletal protein dynamics and identifies progenitor cell markers. Proteomics 11: 3992-4006.
9. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC (1991) Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biol 12: 82-90.
10. Gion M, Mione R, Leon AE, Lüftner D, Molina R, et al. (2001) CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37: 355-363.
11. Molina R, Jo J, Filella X, Zanon G, Pahisa J, et al. (1998) c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51: 109-119.
12. van Dalen A (1990) Pre-operative tumour marker levels in patients with breast cancer and their prognosis. Tumour Biol 11: 189-195.
13. van Dalen A (1996) Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 16: 2345-2349.
14. Baskan Y, Yiayitbaay T (2010) Clinical proteomics of breast cancer. Curr Genomics 11: 528-536.
15. Honrado E, Osorio A, Palacios J, Benitez J (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25: 5837-5845.
16. van der Groep P, van der Wall E, van Diest PJ (2011) Pathology of hereditary breast cancer. Cell Oncol (Dordr) 34: 71-88.
17. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
19. George J, Prasad S, Mahmood Z, Shukla Y (2010) Studies on glyphosateinduced carcinogenicity in mouse skin: a proteomic approach. J Proteomics 73: 951-964.
20. Wessel D, Flügge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141-143.
21. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, et al. (2004) Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25: 1327-1333.
22. Arora A, Seth K, Shukla Y (2004) Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 25: 941-949.
23. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857-872.
24. Wang Y, Kuramitsu Y, Yoshino S, Takashima M, Zhang X, et al. (2011) Screening for serological biomarkers of pancreatic cancer by two-dimensional electrophoresis and liquid chromatography-tandem mass spectrometry. Oncol Rep 26: 287-292.
25. Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, et al. (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179: 1110-1119.
26. Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804.
27. Gräwert MA, Groll M (2012) Exploiting nature's rich source of proteasome inhibitors as starting points in drug development. Chem Commun (Camb) 48: 1364-1378.
28. Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF (2009) Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol 296: F875-883.
29. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, et al. (2012) Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med 185: 373-381.
30. Ikari Y, Mulvihill E, Schwartz SM (2001) alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells. J Biol Chem 276: 11798-11803.
31. Yang P, Wentzlaff KA, Katzmann JA, Marks RS, Allen MS, et al. (1999) Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 8: 461-465.
32. Sriwanitchrak P, Viyanant V, Chaijaroenkul W, Srivatanakul P, Gram HR, et al. (2011) Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev 12: 1503-1510.
33. Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, et al. (1999) Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol 154: 457-468.
34. Xie LQ, Zhao C, Cai SJ, Xu Y, Huang LY, et al. (2010) Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 9: 4701-4709.
35. Scuderi P, Dorr RT, Liddil JD, Finley PR, Meltzer P, et al. (1989) Alphaglobulins suppress human leukocyte tumor necrosis factor secretion. Eur J Immunol 19: 939-942.
36. López-Árias E, Aguilar-Lemarroy A, Felipe Jave-Suárez L, Morgan-Villela G, Mariscal-Ramírez I, et al. (2012) Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer. Electrophoresis 33: 2130-2137.
37. Wright LC, Sullivan DR, Muller M, Dyne M, Tattersall MH, et al. (1989) Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer 43: 241-244.
38. Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L, et al. (2011) Apolipoprotein A1-75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep 38: 1637-1643.
39. Lane DM, Boatman KK, McConathy WJ (1995) Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res Treat 34: 161-169.
40. Grundy SM, Vega GL (1990) Role of apolipoprotein levels in clinical practice. Arch Intern Med 150: 1579-1582.
41. Gao F, Vasquez SX, Su F, Roberts S, Shah N, et al. (2011) L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/ basic FGF signaling pathways. Integr Biol (Camb) 3: 479-489.
42. Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L, et al. (2011) Apolipoprotein A1-75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep 38: 1637-1643.
43. Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, et al. (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
44. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, et al. (2009) Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 11: 52-57.
45. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, et al. (2001) Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290: 302-313.
46. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, et al. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107: 19997-20002.
47. Morrison JA, Sprecher DL, Biro FM, Apperson-Hansen C, Dipaola LM (2002) Serum testosterone associates with lower high-density lipoprotein cholesterol in black and white males, 10 to 15 years of age, through lowered apolipoprotein AI and AII concentrations. Metabolism 51: 432-437.
48. Lei T, Zhao X, Jin S, Meng Q, Zhou H, et al. (2013) Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clin Genitourin Cancer 11: 56-62.
49. Reisher SR, Hughes TE, Ordovas JM, Schaefer EJ, Feinstein SI (1993) Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2. Proc Natl Acad Sci U S A 90: 5757-5761.
50. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, et al. (2007) Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 30: 849-855.
51. Wang X, Dai S, Zhang Z, Liu L, Wang J, et al. (2009) Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl) 18: 625-635.
52. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, et al. (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890.
53. Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, et al. (2006) Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27: 1641-1650.
54. Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, et al. (2007) 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 28: 4302-4310.
55. Lai CQ, Parnell LD, Ordovas JM (2005) The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 16: 153-166.
56. Park JY, Park JH, Jang W, Hwang IK, Kim IJ, et al. (2012) Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases. J Biochem 151: 291-298.
57. Custodio A, López-Farré AJ, Zamorano-León JJ, Mateos-Cáceres PJ, Macaya C, et al. (2012) Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. J Cancer Res Clin Oncol 138: 867-875.
58. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, et al. (2003) Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 44: 1523-1529.
59. Wang H, Sama AE (2012) Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med 12: 625-633.
60. Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, et al. (2004) alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res 64: 6402-6409.
61. Claeyssens S, Banine F, Rouet P, Lavoinne A, Salier JP (1998) Downregulation of negative acute-phase response genes by hypotonic stress in HepG2 hepatoma cells. FEBS Lett 433: 15-18.
62. Daveau M, Christian-Davrinche, Julen N, Hiron M, Arnaud P, et al. (1988) The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 241: 191-194.
63. Yi JK, Chang JW, Han W, Lee JW, Ko E, et al. (2009) Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev 18: 1357-1364.
64. Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, et al. (2009) Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 208: 970-978.